急性淋巴细胞白血病患儿化疗相关中枢神经系统损伤的研究进展

王蕾 ,  沈南平 ,  石思瑶 ,  杜苗 ,  严佳清 ,  蒋颖

中国当代儿科杂志 ›› 2026, Vol. 28 ›› Issue (9) : 1163 -1169.

PDF (601KB)
中国当代儿科杂志 ›› 2026, Vol. 28 ›› Issue (9) : 1163 -1169. DOI: 10.7499/j.issn.1008-8830.2507052
综述

急性淋巴细胞白血病患儿化疗相关中枢神经系统损伤的研究进展

作者信息 +

Chemotherapy-related central nervous system injury in children with acute lymphoblastic leukemia: research progress

Author information +
文章历史 +
PDF (614K)

摘要

急性淋巴细胞白血病是最常见的儿童恶性肿瘤。随着医疗技术水平的提升,虽然患儿的生存率得以显著提高,但化疗相关中枢神经系统损伤问题日益凸显,严重影响患儿的神经功能预后和生活质量。该文综述了急性淋巴细胞白血病患儿化疗相关中枢神经系统损伤的临床表现、影像学与生物标志物诊断、药物毒性机制,并探讨了当前的治疗干预策略与存在的管理挑战。目前缺乏系统化的干预方案与分阶段管理路径,未来需结合治疗阶段及化疗方案制定更精准的中枢神经系统损伤预防管理策略。该综述旨在为临床医护人员深入理解急性淋巴细胞白血病患儿化疗相关中枢神经系统损伤的机制、识别与长期管理提供参考。

Abstract

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. Although therapeutic advances have markedly improved survival, chemotherapy-related central nervous system (CNS) injury is increasingly recognized as a major determinant of neurofunctional outcomes and quality of life. This review summarizes the clinical manifestations, imaging characteristics, and biomarker-based approaches to diagnosing chemotherapy-related CNS injury in children with ALL; outlines drug-induced neurotoxic mechanisms; and discusses current therapeutic and supportive interventions alongside persistent management challenges. There is no standardized, stage-specific care pathway or integrated intervention program at present. Future strategies should align prevention and management with treatment phase and chemotherapy regimen to achieve more precise CNS protection. This review aims to provide information for clinical healthcare professionals to deepen their understanding of the mechanisms, identification, and long-term management of chemotherapy-related CNS injury in children with ALL.

关键词

急性淋巴细胞白血病 / 中枢神经系统 / 化疗 / 神经毒性 / 儿童

Key words

Acute lymphoblastic leukemia / Central nervous system / Chemotherapy / Neurotoxicity / Child

引用本文

引用格式 ▾
王蕾,沈南平,石思瑶,杜苗,严佳清,蒋颖. 急性淋巴细胞白血病患儿化疗相关中枢神经系统损伤的研究进展[J]. 中国当代儿科杂志, 2026, 28(9): 1163-1169 DOI:10.7499/j.issn.1008-8830.2507052

登录浏览全文

4963

注册一个新账户 忘记密码

急性淋巴细胞白血病(acute lymphoblastic leukemia, ALL)是最常见的儿童恶性肿瘤,约占儿童癌症病例的25%[1]。目前,化疗是ALL的主要治疗手段,通常采取2~3年分阶段联合化疗方案。随着ALL的治疗方案不断优化,我国ALL患儿5年无事件生存率已提高至80.3%,总生存率达91.1%[2]。ALL患儿生存率的提升使临床关注的重点从延长生命周期转向改善患儿的生活质量与神经发育,其中化疗相关中枢神经系统(central nervous system, CNS)毒性日益受到重视[3]。
化疗药物的神经毒性可通过炎症反应、代谢紊乱等机制损伤CNS的结构与功能,引发急性及慢性神经系统并发症。在Anastasopoulou等[4]的研究中,9.2%的ALL患儿在治疗中至少发生1次CNS毒性事件。急性CNS症状可表现为癫痫、卒中样症状、意识障碍等,多为可逆性改变,多数患儿可完全恢复[5],但有研究报道病死率可达20.6%[6]。慢性CNS症状则以认知功能下降最为常见,包括注意力不集中、执行功能障碍和记忆力减退[7];还可能合并出现情绪异常、行为问题及感知功能减退等症状[8]。这些损伤不仅影响患儿的神经发育,还可能持续限制其学习和社会适应能力,降低生活质量。本综述对国内外有关ALL患儿化疗相关CNS损伤的文献进行了总结、梳理,旨在为临床医护人员深入理解ALL患儿化疗相关CNS损伤的机制、识别与长期管理提供参考。

1 化疗相关的CNS损伤

1.1 CNS损伤的概述

CNS损伤是指由多种内外部因素导致的大脑、脊髓等CNS组织结构和功能异常,进而引发认知障碍、行为问题、感知异常等神经学症状[9]。化疗相关的CNS损伤在ALL患儿中可表现为急性或慢性神经系统症状,常见症状包括头痛、嗜睡、癫痫发作、意识模糊、视听觉下降等[10]。影像学上最常见的表现为脑白质病变和以枕叶/顶叶为主的脑白质水肿,这类结构改变会破坏脑区之间的神经网络连接,干扰大脑信息整合,导致注意力不集中、记忆力减退及执行功能下降等认知障碍[11]。有研究显示,ALL患儿化疗相关CNS损伤可发生于不同治疗阶段,其中约38%发生于诱导期,30%发生于早期维持治疗期,23%发生于晚期维持治疗期[12]。

1.2 临床表现类型

1.2.1 急性CNS症状

急性CNS毒性通常发生在鞘内或静脉内氨甲蝶呤(methotrexate, MTX)输注后3周内,表现为卒中样症状、癫痫发作、精神状态改变或失语,部分患儿还可能出现可逆性后部脑病综合征[9,12],其典型特征为脑血管源性水肿,多累及双侧枕叶和顶叶[13]。一项为期10年的单中心研究结果显示,约有10%的ALL患儿在治疗过程中出现急性神经毒性[6]。尽管急性CNS毒性的症状通常会随着时间的推移而改善,但临床症状的改善并不意味着未发生不可逆的神经结构损伤。急性期的脑白质损伤和神经网络功能紊乱,可能导致信息传递效率的降低,进而导致认知功能的长期受损[14]。这表明急性期缓解并不等同于完全恢复,部分患儿可能因潜在的神经结构损伤而使其学习能力与社会功能长期受限,从而降低患儿的生活质量。

1.2.2 慢性CNS症状

除急性神经系统表现外,化疗还可能导致持续性神经功能损害。慢性CNS毒性通常表现为患儿的执行功能下降、记忆力减退、注意力缺失等认知问题[15],常与脑白质病变等CNS结构损伤密切相关[16]。有研究显示,高达80%的ALL患儿在治疗期间出现脑白质的结构性改变,若不及时干预可进展为白质脑病[17]。

1.2.3 情绪、行为及感知障碍

ALL患儿在化疗过程中还可能表现出多种情绪异常、行为问题与感知功能异常。情绪异常表现为焦虑、抑郁或情绪不稳定等;行为问题则包括注意力缺陷、攻击性行为、退行及社交退缩等[18]。部分患儿还会出现视听感知异常,如视觉模糊、听力下降或体感迟钝等,这些通常与长期的认知损伤、行为模式改变及心理应激反应密切相关[19-20]。

2 发病机制

2.1 药物毒性机制

药物的神经毒性是导致CNS损伤的重要因素之一。门冬酰胺酶、长春新碱及阿糖胞苷等ALL化疗药物对CNS的神经毒性已被多项研究证实[21-22]。MTX是对CNS影响最大的化疗药物,能够穿过血脑屏障,导致患儿发生CNS毒性的风险升高[23-24]。ALL患儿MTX化疗相关神经毒性的发病率在3%~12%之间[25-26],MTX相关的临床神经毒性症状大多是可自行恢复的。然而,在Bhojwani等[27]的研究中,所有有症状的患者和1/5的无症状患者在后期会发生白质脑病,即使使用四氢叶酸解救也无法完全避免这种脑结构改变[28]。MTX神经毒性的机制为竞争性抑制二氢叶酸还原酶,导致叶酸缺乏,进而阻断DNA合成与修复,影响神经元及胶质细胞功能。同时,MTX导致的叶酸缺乏可使同型半胱氨酸及其代谢产物(如同型半胱氨酸硫内酯)水平升高,诱发兴奋性毒性和氧化应激反应,从而造成髓鞘和神经元损伤[29]。

除MTX外,其他常用化疗药物的神经毒性也可引发CNS损伤(表1)。脂质体阿糖胞苷与全身化疗药物(如长春新碱)联用时,可能通过药物间的药代动力学相互作用叠加毒性反应,从而显著增加发生CNS毒性的风险[30]。虽然蒽环类药物不能穿过血脑屏障,但细胞因子可通过氧化应激机制损害神经元[31]。在儿童频繁使用皮质类固醇治疗期间,研究者观察到实质性的行为和精神变化[32]。此外,化疗药物的剂量累积效应也会大幅度增加发生CNS毒性的风险。

2.2 氧化应激、炎症与细胞凋亡机制

化疗药物可通过诱导自由基生成、激活小胶质细胞和星形胶质细胞等途径,引发氧化应激和炎症反应,导致神经元及胶质细胞损伤或凋亡。化疗药物,如MTX和环磷酰胺能够通过激活小胶质细胞和星形胶质细胞,释放促炎细胞因子,进一步加剧神经炎症并损伤神经元[36-37]。长春新碱、地塞米松和MTX等化疗药物可直接诱导大脑皮质及皮质下区域的神经元及胶质细胞凋亡[38]。炎症反应在化疗相关神经毒性中起核心作用,其级联过程可破坏神经突触可塑性。

2.3 血脑屏障与神经递质机制

化疗药物可能通过破坏血脑屏障和干扰神经递质平衡,加剧CNS损伤。化疗药物可损伤血脑屏障内皮细胞的紧密连接蛋白,增加其通透性,使毒性物质和免疫细胞更容易进入脑实质,从而引发炎症反应[39]。化疗药物还可能通过干扰谷氨酸-谷氨酰胺循环,从而抑制星形胶质细胞对谷氨酸的摄取与转化,导致细胞外谷氨酸浓度升高[40]。过高的谷氨酸浓度会过度激活N‑甲基‑D‑天冬氨酸受体,进而引发兴奋性毒性,导致神经元损伤和凋亡[41]。

2.4 大脑结构改变与功能损害的相关机制

化疗可能会引发多种中枢神经结构与功能异常,包括髓鞘损伤、白质与灰质体积减小、皮层厚度下降、神经网络连接异常,以及海马功能受损等。既往研究表明,MTX定向CNS化疗可能导致大脑灰质体积减小和白质完整性丧失,累及皮层及皮层下多处关键区域(杏仁核、海马、尾状核、丘脑),并会伴随区域脑血流改变和神经元密度下降[41-43]。Bansal等[44]的研究证实,灰质减少、脑血流降低的程度与鞘内注射MTX的剂量呈正相关。Guo等[45]的研究显示,化疗对轴突和髓鞘的损伤并不均衡,髓鞘损伤程度更严重,可能会显著降低神经信号的传导效率。褚思嘉等[46]的研究显示,接受化疗的患儿普遍可表现出大规模灰质结构网络的异常,即区域连通性下降和结构协方差网络效率降低,对注意、记忆、语言、决策及情绪调节等高级认知与情感功能可能造成不良影响。

3 诊断方法

针对CNS损伤的影像学和神经电生理检查包括计算机断层扫描、磁共振成像、功能性磁共振成像、脑电图和诱发电位等。计算机断层扫描虽然在急性期脑出血或水肿的检测中具有较高的敏感性[47],但对于化疗引起的慢性或微小结构变化的神经损伤的敏感性较低。磁共振成像在早期发现脑白质损伤、脑萎缩和水肿等结构性改变方面更具优势[48]。功能性磁共振成像可用于评估化疗对大脑功能活动的影响,揭示化疗对脑功能的潜在影响和神经适应性变化[49]。脑电图则用于监测癫痫发作及其他异常脑电活动变化[50],而诱发电位则可评估视觉、听觉或体感通路的传导延迟或损伤[51]。

此外,化疗相关CNS损伤可通过胶质纤维酸性蛋白水平和髓鞘碱性蛋白水平等脑脊液生物标志物进行评估[52]。治疗结束5年后白质脑病风险增加以及额叶表观弥散系数降低与胶质纤维酸性蛋白、髓鞘碱性蛋白和总tau蛋白水平的升高相关[52]。Hooke等[53]的研究显示,在维持治疗期间,家长报告的患儿认知功能水平与白细胞介素-8水平呈负相关,认知测试得分与8-异前列腺素F2α水平呈负相关。尽管这些标志物在CNS损伤的预测与监测中具有潜在价值,但尚未广泛应用于临床。

4 药物神经毒性的管理策略

目前,ALL患儿CNS损伤的干预策略主要包括预防性治疗、血药浓度监测、剂量管理与对症支持治疗。在CNS神经毒性发作期,治疗以亚叶酸钙解救为主,并辅以支持治疗、对症治疗和密切监测[54]。针对因长春新碱或MTX引起的神经毒性,可根据症状的严重程度减量或替换药物,但剂量调整需权衡疗效与复发风险,且替代药物的疗效和可及性有限。在对症治疗方面,可用抗癫痫药物控制CNS毒性导致的癫痫发作。针对尚未发生神经毒性的ALL患儿,则以预防性治疗、血药浓度监测与对症治疗为主。预防性治疗包括临床应用神经保护剂,如N-乙酰半胱氨酸作为抗氧化剂可减轻MTX引起的CNS毒性;此外,维生素E作为抗氧化剂也被尝试用于预防化疗相关的神经损伤,但临床证据尚不充分[37]。在监测与药物剂量调整方面,由于MTX的药物代谢存在较大的个体差异,其毒性风险难以准确预测,临床多依靠定期血药浓度监测、剂量调整,以及辅助治疗措施,如水化碱化尿液、器官保护药物使用等,以降低毒性风险[55]。

总体而言,虽然临床上已有多种ALL患儿CNS毒性的防治措施,但整体来看,尚未形成覆盖预防、监测、评估与干预的系统化管理路径。目前的治疗干预多依赖临床经验判断,缺乏统一的干预方案和随访监测流程,尤其是在时间维度上缺少明确的监测节点与随访节点。鉴于化疗不同阶段的CNS神经毒性在发生率、类型和严重程度上存在差异,并且不同化疗方案对个体的影响不尽相同,未来研究应着力于构建与治疗阶段相匹配、分阶段的CNS损伤防控策略,以实现更早期识别、更精准干预和更长期管理,最大限度地保护患儿的神经功能,提高患儿的生存质量。

5 小结

本文系统梳理了ALL患儿在化疗期间可能出现的CNS损伤的类型及表现、病理机制、诊断方法及CNS毒性管理策略。在治疗过程中,医护人员不仅应关注ALL患儿的急性神经症状,更应重视患儿在注意力、记忆力、执行功能等方面的早期改变,防止慢性神经毒性被忽视。其次,影像学检查、生物标志物等辅助技术有望用于CNS损伤高风险人群的早期筛查、早期诊断,以此来及早干预ALL患儿的CNS损伤。综上所述,本综述不仅有利于深化医护人员对ALL化疗相关CNS损伤的机制理解,提高对ALL患儿CNS损伤风险的识别能力,并为优化神经毒性的长期管理方案提供了参考。未来可进一步探索多模态影像、生物标志物联合预警模型,早期发现CNS损伤高风险患儿,早期干预,改善预后。

参考文献

[1]

Inaba H, Pui CH. Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia [J]. J Clin Med, 2021, 10(9): 1926. PMCID: PMC8124693. DOI: 10.3390/jcm10091926 .

[2]

Tang J, Yu J, Cai J, et al. Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation[J]. Blood, 2021, 138(4): 331-343. PMCID: PMC8323972. DOI: 10.1182/blood.2020010438 .

[3]

Birenboim SB, Rabinowicz R. Acute therapy-related toxicities in pediatric acute lymphoblastic leukemia[J]. Haematologica, 2025, 110(9): 1923-1933. PMCID: PMC12399958. DOI: 10.3324/haematol.2024.285702 .

[4]

Anastasopoulou S, Nielsen RL, Als-Nielsen B, et al. Acute central nervous system toxicity during treatment of pediatric acute lymphoblastic leukemia: phenotypes, risk factors and genotypes[J]. Haematologica, 2022, 107(10): 2318-2328. PMCID: PMC9521239. DOI: 10.3324/haematol.2021.280016 .

[5]

Kranjčec I, Rajačić N, Janjić T, et al. Acute neurotoxicity in children treated for acute lymphoblastic leukemia and lymphoblastic lymphoma: a 10-year single-centre experience[J]. Children (Basel), 2025, 12(1): 31. PMCID: PMC11763474. DOI: 10.3390/children12010031 .

[6]

Rahiman EA, Rajendran A, Sankhyan N, et al. Acute neurological complications during acute lymphoblastic leukemia therapy: a single-center experience over 10 years[J]. Indian J Cancer, 2021, 58(4): 545-552. DOI: 10.4103/ijc.IJC_422_19 .

[7]

Roganovic J, Haupt R, Bárdi E, et al. Late adverse effects after treatment for childhood acute leukemia[J]. Acta Med Acad, 2024, 53(1): 59-80. PMCID: PMC11237916. DOI: 10.5644/ama2006-124.438 .

[8]

Keleş Gülnerman E, Çam Y, Elbasan B, et al. The contribution of neurocognitive situation, physical capacity and daily life activities to quality of life in childhood acute lymphoblastic leukemia survivors[J]. Turk J Med Sci, 2021, 51(5): 2510-2515. PMCID: PMC8742482. DOI: 10.3906/sag-2010-299 .

[9]

Ekici A, Ayan B, Kazancı EG, et al. Central nervous system complications during treatment in childhood acute leukemia[J]. Acta Neurol Belg, 2025, 125(1): 77-88. DOI: 10.1007/s13760-024-02602-0 .

[10]

Thastrup M, Duguid A, Mirian C, et al. Central nervous system involvement in childhood acute lymphoblastic leukemia: challenges and solutions[J]. Leukemia, 2022, 36(12): 2751-2768. PMCID: PMC9712093. DOI: 10.1038/s41375-022-01714-x .

[11]

Mavrea K, Efthymiou V, Katsibardi K, et al. Cognitive function of children and adolescent survivors of acute lymphoblastic leukemia: a meta-analysis[J]. Oncol Lett, 2021, 21(4): 262. PMCID: PMC7882890. DOI: 10.3892/ol.2021.12523 .

[12]

Hamoda A, Bedair M, Semary SF, et al. Patterns and outcomes of acute central nervous system complications during treatment of childhood acute lymphoblastic leukemia: a single-center experience[J]. J Pediatr Hematol Oncol, 2024, 46(2): 72-79. DOI: 10.1097/MPH.0000000000002797 .

[13]

Ramanathan S, Subramani V, Kembhavi S, et al. Clinical features, predictors and outcome of posterior reversible encephalopathy syndrome (PRES) in children with hematolymphoid malignancies[J]. Childs Nerv Syst, 2022, 38(9): 1689-1698. DOI: 10.1007/s00381-022-05557-w .

[14]

Harris RD, Taylor OA, Raghubar KP, et al. Episodes of acute methotrexate-related neurotoxicity linked to compromised long-term neurocognitive function[J]. Pediatr Blood Cancer, 2024, 71(9): e31169. PMCID: PMC11514057. DOI: 10.1002/pbc.31169 .

[15]

覃李娇, 麦惠容. 急性淋巴细胞白血病儿童认知功能损害的临床研究进展[J]. 中国当代儿科杂志, 2023, 25(3): 315-320. PMCID: PMC10032075. DOI: 10.7499/j.issn.1008-8830.2210063 .

[16]

褚思嘉, 汤继宏, 张兵兵, 等. 儿童急性淋巴细胞白血病化疗伴发白质脑病的临床特点及远期随访[J]. 中国小儿血液与肿瘤杂志, 2024, 29(5): 332-336, 343. DOI: 10.3969/j.issn.1673-5323.2024.05.006 .

[17]

Schroyen G, Meylaers M, Deprez S, et al. Prevalence of leukoencephalopathy and its potential cognitive sequelae in cancer patients[J]. J Chemother, 2020, 32(7): 327-343. DOI: 10.1080/1120009X.2020.1805239 .

[18]

Peng L, Yang LS, Yam P, et al. Neurocognitive and behavioral outcomes of Chinese survivors of childhood lymphoblastic leukemia[J]. Front Oncol, 2021, 11: 655669. PMCID: PMC8093634. DOI: 10.3389/fonc.2021.655669 .

[19]

Phillips NS, Duke ES, Schofield HT, et al. Neurotoxic effects of childhood cancer therapy and its potential neurocognitive impact[J]. J Clin Oncol, 2021, 39(16): 1752-1765. PMCID: PMC8260913. DOI: 10.1200/JCO.20.02533 .

[20]

Latoch E, Zubowska M, Młynarski W, et al. Late effects of childhood cancer treatment in long-term survivors diagnosed before the age of 3 years: a multicenter, nationwide study[J]. Cancer Epidemiol, 2022, 80: 102209. DOI: 10.1016/j.canep.2022.102209 .

[21]

Laniel J, Sultan S, Sinnett D, et al. Cumulative dosage of intrathecal chemotherapy agents predicts white matter integrity in long-term survivors of acute lymphoblastic leukemia: a PETALE study[J]. Cancers (Basel), 2024, 16(6): 1208. PMCID: PMC10969288. DOI: 10.3390/cancers16061208 .

[22]

Joo J, Yang WS, Koh HJ. Molecular and mechanistic divergence of seizures in pediatric acute lymphoblastic leukemia: CNS infiltration versus chemotherapy-induced neurotoxicity[J]. Int J Mol Sci, 2026, 27(7): 3307. PMCID: PMC13073153. DOI: 10.3390/ijms27073307 .

[23]

Apiraksattayakul N, Jitprapaikulsan J, Sanpakit K, et al. Potential neurotoxicity associated with methotrexate[J]. Sci Rep, 2024, 14(1): 18548. PMCID: PMC11315891. DOI: 10.1038/s41598-024-69263-0 .

[24]

Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia[J]. Haematologica, 2020, 105(11): 2524-2539. PMCID: PMC7604619. DOI: 10.3324/haematol.2020.247031 .

[25]

Mateos MK, Marshall GM, Barbaro PM, et al. Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia[J]. Haematologica, 2022, 107(3): 635-643. PMCID: PMC8883571. DOI: 10.3324/haematol.2020.268565 .

[26]

Śliwa-Tytko P, Kaczmarska A, Lejman M, et al. Neurotoxicity associated with treatment of acute lymphoblastic leukemia chemotherapy and immunotherapy[J]. Int J Mol Sci, 2022, 23(10): 5515. PMCID: PMC9146746. DOI: 10.3390/ijms23105515 .

[27]

Bhojwani D, Sabin ND, Pei D, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia[J]. J Clin Oncol, 2014, 32(9): 949-959. PMCID: PMC3948096. DOI: 10.1200/JCO.2013.53.0808 .

[28]

Pryweller JR, Glass JO, Sabin ND, et al. Characterization of leukoencephalopathy and association with later neurocognitive performance in pediatric acute lymphoblastic leukemia[J]. Invest Radiol, 2021, 56(2): 117-126. PMCID: PMC8059361. DOI: 10.1097/RLI.0000000000000715 .

[29]

Dabagh S, David H, Young S, et al. Severe, fatal methotrexate-related neurotoxicity in 2 adolescent patients with ALL[J]. J Pediatr Hematol Oncol, 2020, 42(8): e839-e844. PMCID: PMC7469921. DOI: 10.1097/MPH.0000000000001706 .

[30]

Di Francia R, Crisci S, De Monaco A, et al. Response and toxicity to cytarabine therapy in leukemia and lymphoma: from dose puzzle to pharmacogenomic biomarkers[J]. Cancers (Basel), 2021, 13(5): 966. PMCID: PMC7956511. DOI: 10.3390/cancers13050966 .

[31]

Kamińska K, Cudnoch-Jędrzejewska A. A review on the neurotoxic effects of doxorubicin[J]. Neurotox Res, 2023, 41(5): 383-397. PMCID: PMC10499694. DOI: 10.1007/s12640-023-00652-5 .

[32]

Anastasopoulou S, Swann G, Andres-Jensen L, et al. Severe steroid-related neuropsychiatric symptoms during paediatric acute lymphoblastic leukaemia therapy: an observational Ponte di Legno Toxicity Working Group Study [J]. Br J Haematol, 2024, 205(4): 1450-1459. DOI: 10.1111/bjh.19610 .

[33]

van Hulst AM, Grootenhuis MA, Verwaaijen EJ, et al. Unraveling dexamethasone-induced neurobehavioral and sleep problems in children with ALL: which determinants are important?[J]. JCO Precis Oncol, 2023, 7: e2200678. PMCID: PMC10309531. DOI: 10.1200/PO.22.00678 .

[34]

Wu SY, Short NJ, Nasr L, et al. Central nervous system prophylaxis and treatment in acute leukemias[J]. Curr Treat Options Oncol, 2022, 23(12): 1829-1844. PMCID: PMC9767998. DOI: 10.1007/s11864-022-01032-5 .

[35]

Maese L, Rau RE. Current use of asparaginase in acute lymphoblastic leukemia/lymphoblastic lymphoma[J]. Front Pediatr, 2022, 10: 902117. PMCID: PMC9279693. DOI: 10.3389/fped.2022.902117 .

[36]

原琴琴, 周玉敏, 顾兵, 等. 低剂量甲氨蝶呤的抗炎作用机制及其在脊髓损伤中应用[J]. 中国药理学通报, 2017, 33(3): 312-316. DOI: 10.3969/j.issn.1001-1978.2017.03.005 .

[37]

Was H, Borkowska A, Bagues A, et al. Mechanisms of chemotherapy-induced neurotoxicity[J]. Front Pharmacol, 2022, 13: 750507. PMCID: PMC8996259. DOI: 10.3389/fphar.2022.750507 .

[38]

Shao Y, Tan B, Shi J, et al. Methotrexate induces astrocyte apoptosis by disrupting folate metabolism in the mouse juvenile central nervous system[J]. Toxicol Lett, 2019, 301: 146-156. DOI: 10.1016/j.toxlet.2018.11.016 .

[39]

Lee NW, Lee KH. Methotrexate-induced stroke-like leukoencephalopathy[J]. Ann Child Neurol, 2024, 32(3): 193-196. DOI: 10.26815/acn.2024.00507 .

[40]

Alhowail AH. Cisplatin induces hippocampal neurotoxicity and cognitive impairment in rats through neuroinflammation, oxidative stress, and overexpression of glutamatergic receptors mRNA[J]. Front Pharmacol, 2025, 16: 1592511. PMCID: PMC12163336. DOI: 10.3389/fphar.2025.1592511 .

[41]

Almalki RS, Eweis H, Kamal F, et al. Methotrexate toxicity: molecular mechanisms and management[J]. J Pharm Res Int, 2021, 33(49B): 204-217. DOI: 10.9734/JPRI/2021/v33i49B33357 .

[42]

Zou L, Su L, Xu J, et al. Structural brain alteration in survivors of acute lymphoblastic leukemia with chemotherapy treatment: a voxel-based morphometry and diffusion tensor imaging study[J]. Brain Res, 2017, 1658: 68-72. DOI: 10.1016/j.brainres.2017.01.017 .

[43]

Gandy K, Scoggins MA, Jacola LM, et al. Structural and functional brain imaging in long-term survivors of childhood acute lymphoblastic leukemia treated with chemotherapy: a systematic review[J]. JNCI Cancer Spectr, 2021, 5(5): pkab069. PMCID: PMC8421809. DOI: 10.1093/jncics/pkab069 .

[44]

Bansal R, Bhojwani D, Sun BF, et al. Progression of brain injuries associated with methotrexate chemotherapy in childhood acute lymphoblastic leukemia[J]. Pediatr Res, 2025, 97(1): 348-359. PMCID: PMC11798858. DOI: 10.1038/s41390-024-03351-9 .

[45]

Guo J, Han Y, Li Y, et al. Reduced brain microstructural asymmetry in patients with childhood leukemia treated with chemotherapy compared with healthy controls[J]. PLoS One, 2019, 14(5): e0216554. PMCID: PMC6508708. DOI: 10.1371/journal.pone.0216554 .

[46]

褚思嘉, 汤继宏. 儿童急性淋巴细胞白血病及其治疗所伴发的中枢神经系统损伤研究进展[J]. 临床儿科杂志, 2024, 42(9): 811-816. DOI: 10.12372/jcp.2024.23e0892 .

[47]

Deak D, Gorcea-Andronic N, Sas V, et al. A narrative review of central nervous system involvement in acute leukemias[J]. Ann Transl Med, 2021, 9(1): 68. PMCID: PMC7859772. DOI: 10.21037/atm-20-3140 .

[48]

Badr MA, Hassan TH, El-Gerby KM, et al. Magnetic resonance imaging of the brain in survivors of childhood acute lymphoblastic leukemia[J]. Oncol Lett, 2013, 5(2): 621-626. PMCID: PMC3573121. DOI: 10.3892/ol.2012.1072 .

[49]

Fellah S, Cheung YT, Scoggins MA, et al. Brain activity associated with attention deficits following chemotherapy for childhood acute lymphoblastic leukemia [J]. J Natl Cancer Inst, 2019, 111(2): 201-209. PMCID: PMC6376909. DOI: 10.1093/jnci/djy089 .

[50]

Lisgaras CP, de la Prida LM, Bertram E, et al. The role of electroencephalography in epilepsy research: from seizures to interictal activity and comorbidities[J]. Epilepsia, 2025, 66(5): 1374-1393. PMCID: PMC12097480. DOI: 10.1111/epi.18282 .

[51]

Kroczka S, Stepien K, Witek-Motyl I, et al. Clinical utility of complex assessment with evoked potentials in acute lymphoblastic leukemia survivors: comparison of various treatment protocols[J]. BMC Cancer, 2021, 21(1): 150. PMCID: PMC7876796. DOI: 10.1186/s12885-021-07873-x .

[52]

Cheung YT, Khan RB, Liu W, et al. Association of cerebrospinal fluid biomarkers of central nervous system injury with neurocognitive and brain imaging outcomes in children receiving chemotherapy for acute lymphoblastic leukemia[J]. JAMA Oncol, 2018, 4(7): e180089. PMCID: PMC5885182. DOI: 10.1001/jamaoncol.2018.0089 .

[53]

Hooke MC, Mathiason MA, Kunin-Batson AS, et al. Biomarkers and cognitive function in children and adolescents during maintenance therapy for leukemia[J]. Oncol Nurs Forum, 2021, 48(6): 623-633. PMCID: PMC12817264. DOI: 10.1188/21.ONF.623-633 .

[54]

陈福宜, 吴婕翎, 马廉. 儿童急性淋巴细胞白血病长期生存的康复管理[J]. 肿瘤防治研究, 2022, 49(9): 893-898. DOI: 10.3971/j.issn.1000-8578.2022.22.0110 .

[55]

孟岑, 徐刚. 儿童急性淋巴细胞白血病中ABCB1C3435T位点基因多态性对大剂量甲氨蝶呤血药浓度及不良反应的影响[J]. 实用药物与临床, 2021, 24(1): 43-47. DOI: 10.14053/j.cnki.ppcr.202101009 .

AI Summary AI Mindmap
PDF (601KB)

140

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉